Clinical value of serum CA19-9 levels in evaluating resectability of pancreatic carcinoma

World Journal of Gastroenterology

Volumn 14, Issue 23, 2008, Pages 3750-3753

  Zhang, Shun ^a   Wang, Yi Ming ^a   Sun, Chuan Dong ^a   Lu, Yun ^a   Wu, Li Qun ^a  

^a QINGDAO UNIVERSITY   (China)

Author keywords

CA19 9; Pancreatic carcinoma; Receiver operating characteristic curve; Resection; Tumor markers

Indexed keywords

CA 19-9 ANTIGEN;

ADULT; ANTIGEN DETECTION; ARTICLE; FEMALE; HUMAN; INOPERABLE CANCER; LAPAROTOMY; MAJOR CLINICAL STUDY; MALE; PANCREAS BIOPSY; PANCREAS CARCINOMA; PANCREAS RESECTION; PANCREATICODUODENECTOMY; PREOPERATIVE EVALUATION; SENSITIVITY AND SPECIFICITY;

EID: 54349119571     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.3750     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96
2. Wang L, Yang GH, Lu XH, Huang ZJ, Li H. Pancreatic cancer mortality in China (1991-2000). World J Gastroenterol 2003; 9: 1819-1823
3. Warshaw AL, Fernandez-del Castillo C. Pancreatic carcinoma. N Engl J Med 1992; 326: 455-465
4. Tamm EP, Silverman PM, Charnsangavej C, Evans DB. Diagnosis, staging, and surveillance of pancreatic cancer. AJR Am J Roentgenol 2003; 180: 1311-1323
5. Vargas R, Nino-Murcia M, Trueblood W, Jeffrey RB Jr. MDCT in Pancreatic adenocarcinoma: prediction of vascular invasion and resectability using a multiphasic technique with curved planar reformations. AJR Am J Roentgenol 2004; 182: 419-425
6. Wakabayashi H, Nishiyama Y, Otani T, Sano T, Yachida S, Okano K, Izuishi K, Suzuki Y. Role of 18F-fluorodeoxyglucose positron emission tomography imaging in surgery for pancreatic cancer. World J Gastroenterol 2008; 14: 64-69
7. Pisters PW, Lee JE, Vauthey JN, Charnsangavej C, Evans DB. Laparoscopy in the staging of pancreatic cancer. Br J Surg 2001; 88: 325-337
8. Koopmann J, Rosenzweig CN, Zhang Z, Canto MI, Brown DA, Hunter M, Yeo C, Chan DW, Breit SN, Goggins M. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res 2006; 12: 442-446
9. Zou KH, O'Malley AJ, Mauri L. Receiver-operating characteristic analysis for evaluating diagnostic tests and predictive models. Circulation 2007; 115: 654-657
10. Walter SD, Sinuff T. Studies reporting ROC curves of diagnostic and prediction data can be incorporated into meta-analyses using corresponding odds ratios. J Clin Epidemiol 2007; 60: 530-534
11. Altman DG, Bland JM. Diagnostic tests 2: Predictive values. BMJ 1994; 309:102
12. Altman DG, Bland JM. Diagnostic tests 3: receiver operating characteristic plots. BMJ 1994; 309: 188
13. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003; 53: 5-26
14. Pappas S, Federle MP, Lokshin AE, Zeh HJ 3rd. Early detection and staging of adenocarcinoma of the pancreas. Gastroenterol Clin North Am 2007; 36: 413-429, x
15. Takhar AS, Palaniappan P, Dhingsa R, Lobo DN. Recent developments in diagnosis of pancreatic cancer. BMJ 2004; 329: 668-673
16. Misek DE, Patwa TH, Lubman DM, Simeone DM. Early detection and biomarkers in pancreatic cancer. J Natl Compr Canc Netw 2007; 5: 1034-1041
17. Delbeke D, Pinson CW. Pancreatic tumors: role of imaging in the diagnosis, staging, and treatment. J Hepatobiliary Pancreat Surg 2004; 11: 4-10
18. Sahani DV, Shah ZK, Catalano OA, Boland GW, Brugge WR. Radiology of pancreatic adenocarcinoma: current status of imaging. J Gastroenterol Hepatol 2008; 23: 23-33
19. Karmazanovsky G, Fedorov V, Kubyshkin V, Kotchatkov A. Pancreatic head cancer: accuracy of CT in determination of resectability. Abdom Imaging 2005; 30: 488-500
20. Hanbidge AE. Cancer of the pancreas: the best image for early detection - CT, MRI, PET or US? Can J Gastroenterol 2002; 16: 101-105
21. Andersson R, Vagianos C, Williamson R. Preoperative staging and evaluation of resectability in pancreatic ductal adenocarcinoma. HPB (Oxford) 2004; 6: 5-12
22. Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet 1979; 5: 957-971
23. Wu X, Lu XH, Xu T, Qian JM, Zhao P, Guo XZ, Yang XO, Jiang WJ. [The diagnostic value of serum carcinoma markers, fecal K-ras and p53 gene mutation in pancreatic cancers] Zhonghua Neike Zazhi 2005; 44: 741-744
24. Okusaka T, Okada S, Sato T, Wakasugi H, Saisho H, Furuse J, Ishikawa O, Matsuno S, Yokoyama S. Tumor markers in evaluating the response to radiotherapy in unresectable pancreatic cancer. Hepatogastroenterology 1998; 45: 867-872
25. Liao Q, Zhao YP, Yang YC, Li LJ, Long X, Han SM. Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head. Hepatobiliary Pancreat Dis Int 2007; 6: 641-645
26. Kang CM, Kim JY, Choi GH, Kim KS, Choi JS, Lee WJ, Kim BR. The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer. J Surg Res 2007; 140: 31-35
27. Zhao JZ, Wu BH. Clinical significance of CA19-9 in diagnosis of digestive tract tumors. China Nati J New Gastroenterol 1997; 3: 253-254
28. Schlieman MG, Ho HS, Bold RJ. Utility of tumor markers in determining resectability of pancreatic cancer. Arch Surg 2003; 138: 951-955; discussion 955-956
29. Zakowski L, Seibert C, VanEyck S. Evidence-based medicine: answering questions of diagnosis. Clin Med Res 2004; 2: 63-69
30. Kilic M, Gocmen E, Tez M, Ertan T, Keskek M, Koc M. Value of preoperative serum CA 19-9 levels in predicting resectability for pancreatic cancer. Can J Surg 2006; 49: 241-244